Acceptability of a microbicide among women and their partners in a 4-country phase I trial

被引:105
作者
Bentley, ME
Fullem, AM
Tolley, EE
Kelly, CW
Jogelkar, N
Srirak, N
Mwafulirwa, L
Khumalo-Sakutukwa, G
Celentano, DD
机构
[1] Univ N Carolina, Dept Nutr, Carolina Populat Ctr, Chapel Hill, NC 27516 USA
[2] John Snow Inc, Boston, MA USA
[3] Family Hlth Int, Durham, NC USA
[4] Fred Hutchinson Canc Ctr, Seattle, WA USA
[5] Natl AIDS Res Inst, Pune, Maharashtra, India
[6] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand
[7] Johns Hopkins Univ, Coll Med, Res Project, Blantyre, Malawi
[8] Univ Calif San Francisco, Ctr AIDS Prevent, San Francisco, CA USA
[9] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
关键词
D O I
10.2105/AJPH.94.7.1159
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives. We analyzed qualitative and quantitative data for 98 HIV-negative, low-risk women in Malawi, Zimbabwe, India, and Thailand who participated in a safety and acceptability study of BufferGel, a vaginal microbicide to determine the across-country acceptability of vaginal microbicides among women and their partners. Methods. Quantitative survey data were collected at 7 and 14 days after use among enrolled women, and exit interviews were conducted with women and their partners in separate focus group discussions. Results. Acceptability was high in all sites (73% of women approved of the microbicide). Women in Africa, where HIV infection rates are highest, were virtually unanimous in their desire for such a product, suggesting that an individual's perception of being at risk for HIV will outweigh concerns about side effects, problems applying a product, or other factors, when products are shown to be efficacious. But men and women reported that use, which was kept secret from an intimate partner, would be difficult and might "break the trust" of a relationship. Conclusions. Acceptability research across diverse settings through all stages of microbicide research, development, and postlicensure dissemination can help maximize acceptability and use.
引用
收藏
页码:1159 / 1164
页数:6
相关论文
共 32 条
  • [1] ANANNIA A, 2002, MICROBICIDES 2002 M
  • [2] Acceptability of a novel vaginal microbicide during a safety trial among low-risk women
    Bentley, ME
    Morrow, KM
    Fullem, A
    Chesney, MA
    Horton, SD
    Rosenberg, Z
    Mayer, KH
    [J]. FAMILY PLANNING PERSPECTIVES, 2000, 32 (04): : 184 - 188
  • [3] BROWN JM, 2000, 13 INT AIDS C JUL 7
  • [4] Acceptability and feasibility of Micralax® applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides
    Coetzee, N
    Blanchard, K
    Ellertson, C
    Hoosen, AA
    Friedland, B
    [J]. AIDS, 2001, 15 (14) : 1837 - 1842
  • [5] Men's attitudes towards a potential vaginal microbicide in Zimbabwe, Mexico and the USA
    Coggins, C
    Blanchard, K
    Friedland, B
    [J]. REPRODUCTIVE HEALTH MATTERS, 2000, 8 (15) : 132 - 141
  • [6] Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide
    Coggins, C
    Blanchard, K
    Alvarez, F
    Brache, V
    Weisberg, E
    Kilmarx, PH
    Lacarra, M
    Massai, R
    Mishell, D
    Salvatierra, A
    Witwatwongwana, P
    Elias, C
    Ellertson, C
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2000, 76 (06) : 480 - 483
  • [7] *CTR DIS CONTR PRE, 2001, NAT HIV AIDS SURV RE
  • [8] DARROCH JE, 1994, INT FAM PLAN PERSPEC, V31, P16
  • [9] Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going?
    Elias, C
    Coggins, C
    [J]. JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2001, 10 (02): : 163 - 173
  • [10] *FAM HLTH INT, 2004, AIDS CONT PREV WOM I